30 closest matches · ranked by relevance
HPV-Related Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) at 2 Years — 75.5 percentage of patients
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma
Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: 2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous…
Head and Neck Squamous Cell Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Event (SAEs) — 6; 15; 2; 0 Participants
Vaginal Cancer · Cervical Cancer · Anal Cancer
Primary: Maximum Tolerated Dose (MTD) — 2 # of cells x 10^11
Squamous Cell Carcinoma of Oropharynx
Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Pathologic Complete Response Rate After De-escalated CRT in HPV-positive and/or p16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC). — 37 Participants
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
Papillomavirus Infections · Cervical Intraepithelial Neoplasia · Carcinoma In Situ
Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants
Cervical Adenocarcinoma · Cervical Squamous Cell Carcinoma · Human Papillomavirus Infection
Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events
Head and Neck Cancer · Human Papilloma Virus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 15; 9; 11; 4 Participants
Cancer of Head and Neck · Cancer of Cervix · Cancer of Anus
Primary: Number of Participants With Dose Limiting Toxicity (DLT) [Phase 1b] — 0 Participants
Human Papilloma Virus Infection · Stage III Squamous Cell Carcinoma of the Oropharynx · Stage IVA Squamous Cell Carcinoma of the Oropharynx
Primary: Progression-Free Survival (PFS), Evaluated Using RECIST Version (v) 1.1 — 94.5 percentage of participants
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants
Human Papillomavirus Infection · Stage I Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma
Primary: 2-year Loco-regional Tumor Control (LRC) Rate — 100; 93; 96.2 percentage of patients
Effects of Immunotherapy · Metastatic/Recurrent Cervical Cancer · Cervical Adenocarcinoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration
Human Papilloma Virus · Cervical Cancer · Oropharyngeal Cancer
Primary: Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response — 31; 7.7 percentage of participants
Human Papillomavirus (HPV)-Related Malignancies · Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Primary: Radiographic Responses, Determined by RECIST 1.1 Criteria — 5; 4; 3 Participants
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Oropharynx Cancer
Primary: Grade 3+ Adverse Events Rate — .032; .115 events per participant
HEAD & NECK Cancer
Primary: To Explore if Ribavirin Therapy for 2 Weeks Decreases Tumor Expression — 4; 2; 3 Participants
Squamous Cell Carcinoma of the Oropharynx · HPV
Primary: Rate of Recurrence — 8 Participants
Head and Neck Cancer · Precancerous Condition
Primary: 24-month Progression-free Survival — 64 percentage of participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
HIV-1 Infection
Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons